AlisonJillMoskowitzMD

Hematologic Oncology

Assistant Attending, Memorial Sloan Kettering Cancer Center

Overview of Dr. Moskowitz

Dr. Alison Moskowitz is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 14 years. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 89 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(903) 730-6506

Education & Training

New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2003 - 2006
Albert Einstein College of MedicineClass of 2003
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2005 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2018 - 2025
PA State Medical License 2023 - 2024
OR State Medical License 2021 - 2022
American Board of Internal Medicine Hematology

Clinical Trials

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2012 Jan 05
Completed
Phase 2
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Sep 01
Completed
Phase 1
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL Start of enrollment: 2017 Apr 24
Active, not recruiting
Phase 2
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) Start of enrollment: 2017 Jan 25
Recruiting
Phase 1, Phase 2
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma Start of enrollment: 2017 Jun 08
Recruiting
Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients Start of enrollment: 2018 Jul 03
Recruiting
Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2018 Aug 01
Recruiting
Phase 2
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type Start of enrollment: 2018 Nov 09
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome Start of enrollment: 2021 Oct 01
Recruiting
Phase 2
A Study of Ruxolitinib and Duvelisib in People With Lymphoma Start of enrollment: 2021 Aug 12
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas Start of enrollment: 2017 Jun 07
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
A Registry for People With T-cell Lymphoma Start of enrollment: 2023 Jul 27
Recruiting
Roles: Contact
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia Start of enrollment: 2023 May 03
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Pallawi Torka, Tatyana Feldman, Kerry J Savage, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2024-12-11
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Steven M Horwitz, Ajit J Nirmal, Jahan Rahman, Ran Xu, Esther Drill
Nature Medicine. 2024-12-01
Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma.
Jeremy S Abramson, Robert Stuver, Alex Herrera, Emily Patterson, Yi-Ping Wen
Critical Reviews in Oncology/hematology. 2024-12-01

Abstracts/Posters

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Alison J. Moskowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
Alison J. Moskowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
Alison J. Moskowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
Alison J. Moskowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
Alison J. Moskowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
Alison J. Moskowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
Alison J. Moskowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Pre-Transplant Salvage Options: Bringing Conventional Versus Novel Combinations to Practice
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Circulating Lymphoma Cells in Mycosis Fungoides/Sezary Syndrome Show Heterogeneity of the Cell-of-Origin and Variable PD-1 Expression By Flow Cytometric Analysis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

New Combination Data of Secura Bio’s COPIKTRA® (Duvelisib) Presented at the 2024 American Society of Hematology MeetingDecember 9th, 2024
What's on Tap at the Society of Hematologic Oncology's 10th Annual MeetingSeptember 26th, 2022
Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin LymphomaJune 4th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member